カテゴリー：世界, 医療/バイオ, visiongain

世界の髄膜炎菌ワクチン市場2023年～2033年

【英語タイトル】Meningococcal Vaccines Market Report 2023-2033 : Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by Vaccine Brand (Bexsero, Menactra, Menveo, Others), by End-users (Pediatric, Adult, Travelers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
	・商品コード：VGA23FB017 ・発行会社（調査会社）：visiongain ・発行日：2023年1月31日・ページ数：214 ・レポート言語：英語・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内）・調査対象地域：グローバル・産業分野：医薬品

◆販売価格オプション（消費税別）

Sigle User（1名様閲覧用、1年間、印刷不可）	GBP3,950 ⇒換算￥750,500	見積依頼/購入/質問フォーム
Enterprise（法人閲覧用、1年間、印刷可）	GBP6,950 ⇒換算￥1,320,500	見積依頼/購入/質問フォーム

※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）

❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界の髄膜炎菌ワクチン市場規模が2033年までに年平均6.32%で成長すると予測しています。本レポートは、髄膜炎菌ワクチンの世界市場を徹底調査し、レポート概要、エグゼクティブサマリー、市場動向、ワクチン種類別（複合体、多糖類、その他）分析、ワクチンブランド別（ベクセロ、メナクトラ、メンベオ、その他）分析、エンドユーザー別（小児、大人、旅行者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、企業情報などの内容を作成しました。本書には、BIO-MED、GSK plc、Incepta Pharmaceuticals Ltd.、Merck & Co., Inc.、Pfizer Inc.、Sanofi、Serum Institute of India Pvt. Ltd.、Walvax Biotechnology Co., Ltd.、Zhi Fei Biologicalなどの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・世界の髄膜炎菌ワクチン市場規模：ワクチン種類別
- 複合体ワクチンの市場規模
- 多糖類ワクチンの市場規模
- その他ワクチンの市場規模
・世界の髄膜炎菌ワクチン市場規模：ワクチンブランド別
- ベクセロの市場規模
- メナクトラの市場規模
- メンベオの市場規模
- その他ワクチンブランドの市場規模
・世界の髄膜炎菌ワクチン市場規模：エンドユーザー別
- 小児における市場規模
- 大人における市場規模
- 旅行者における市場規模
・世界の髄膜炎菌ワクチン市場規模：地域別
- 北米の髄膜炎菌ワクチン市場規模
- ヨーロッパの髄膜炎菌ワクチン市場規模
- アジア太平洋の髄膜炎菌ワクチン市場規模
- 中南米の髄膜炎菌ワクチン市場規模
- 中東・アフリカの髄膜炎菌ワクチン市場規模
・企業情報

The Meningococcal Vaccines Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Meningitis Driving Market Growth
Increasing adoption of meningococcal vaccines and the growing prevalence of meningitis and other viral diseases in developed as well as developing regions is anticipated to drive market growth. Also, the growing investment in R&D and novel drug launches for the treatment of viral diseases is further boosting the market growth. The developed regions including the U.S., Japan, and Europe accounted for a large share in the market is due to the well-developed healthcare infrastructure and better healthcare awareness in developed countries compared to developing countries. Thus, the demand for advanced and more efficient drugs is high in these regions. Whereas the market in emerging economies such as China, India, and South Africa is growing at a high pace owing to government initiatives, growing respiratory health awareness, and increasing disposable income.

What Questions Should You Ask before Buying a Market Research Report?
• How is the meningococcal vaccines market evolving?
• What is driving and restraining the meningococcal vaccines market?
• How will each meningococcal vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each meningococcal vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading meningococcal vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the meningococcal vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
meningococcal vaccines projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the meningococcal vaccines market?
• Where is the meningococcal vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the meningococcal vaccines market today, and over the next 10 years:
• Our 214-page report provides 83 tables and 132 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the meningococcal vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Vaccine Type
• Conjugate
• Polysaccharide
• Others

Vaccine Brand
• Bexsero
• Menactra
• Menveo
• Others

End-users
• Pediatric
• Adult
• Travelers

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Meningococcal Vaccines Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• BIO-MED
• GSK plc
• Incepta Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Walvax Biotechnology Co., Ltd.
• Zhi Fei Biological

Overall world revenue for Meningococcal Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$3,443.4 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Meningococcal Vaccines Market, 2023 to 2033 report help you?
In summary, our 210+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Meningococcal Vaccines Market, 2023 to 2033 Market, with forecasts for Vaccine Type, Vaccine Brand, and End-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Meningococcal Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 9 of the major companies involved in the Meningococcal Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Meningococcal Vaccines Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Meningococcal Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Prevalence of Meningitis
3.2.1.2 Increasing Initiatives by Government and Regulatory Authorities
3.2.1.3 Presence of Non-profit Organizations Providing Funds for Research Projects
3.2.1.4 Vaccine Trials Are Expected to be Commercialized During the Forecast Period
3.2.2 Market Restraining Factors
3.2.2.1 Low Production Rate and High Cost
3.2.2.2 High Costs of Drug Development Limits the Entry of New Players
3.2.2.3 Long Vaccine Manufacturing Timelines to Impede the Growth of the Vaccines Market
3.2.3 Market Opportunities
3.2.3.1 Increasing Inclusion in NIPs Unlocking New Windows of Opportunities
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Supplier: Moderate
3.4.2 Bargaining Power of Buyer: Moderate
3.4.3 Competitive Rivalry: High
3.4.4 Threat of New Entrants: low
3.4.5 Threat of Substitutes: Low
3.5 PEST Analysis
3.5.1 Political Factors Impacting Meningococcal Vaccines Market
3.5.2 Economic Factors Impacting Meningococcal Vaccines Market
3.5.3 Social Factors Impacting Meningococcal Vaccines Market
3.5.4 Technological Factors Impacting Meningococcal Vaccines Market

4 Meningococcal Vaccines Market Analysis by Vaccine Type
4.1 Key Findings
4.2 Vaccine Type Segment: Market Attractiveness Index
4.3 Meningococcal Vaccines Market Size Estimation and Forecast by Vaccine Type
4.4 Conjugate
4.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Polysaccharide
4.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Others
4.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.6.2 Market Share by Region, 2023 & 2033 (%)

5 Meningococcal Vaccines Market Analysis by Vaccine Brand
5.1 Key Findings
5.2 Vaccine Brand Segment: Market Attractiveness Index
5.3 Meningococcal Vaccines Market Size Estimation and Forecast by Vaccine Brand
5.4 Bexsero
5.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Menactra
5.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Menveo
5.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Others
5.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.7.2 Market Share by Region, 2023 & 2033 (%)

6 Meningococcal Vaccines Market Analysis by End-users
6.1 Key Findings
6.2 End-users Segment: Market Attractiveness Index
6.3 Meningococcal Vaccines Market Size Estimation and Forecast by End-users
6.4 Pediatric
6.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Adult
6.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Travelers
6.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Meningococcal Vaccines Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast

8 North America Meningococcal Vaccines Market Analysis
8.1 Key Findings
8.2 North America Meningococcal Vaccines Market Attractiveness Index
8.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
8.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
8.5 Market Size Estimation and Forecast by Vaccine Type, 2023-2033 (US$ Mn)
8.6 Market Size Estimation and Forecast by Vaccine Brand, 2023-2033 (US$ Mn)
8.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
8.8 U.S. Meningococcal Vaccines Market Analysis
8.9 Canada Meningococcal Vaccines Market Analysis

9 Europe Meningococcal Vaccines Market Analysis
9.1 Key Findings
9.2 Europe Meningococcal Vaccines Market Attractiveness Index
9.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
9.5 Market Size Estimation and Forecast by Vaccine Type, 2023-2033 (US$ Mn)
9.6 Market Size Estimation and Forecast by Vaccine Brand, 2023-2033 (US$ Mn)
9.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
9.8 Germany Meningococcal Vaccines Market Analysis
9.9 UK Meningococcal Vaccines Market Analysis
9.10 France Meningococcal Vaccines Market Analysis
9.11 Italy Meningococcal Vaccines Market Analysis
9.12 Spain Meningococcal Vaccines Market Analysis
9.13 Russia Meningococcal Vaccines Market Analysis
9.14 Rest of Europe Meningococcal Vaccines Market Analysis

10 Asia Pacific Meningococcal Vaccines Market Analysis
10.1 Key Findings
10.2 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
10.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
10.5 Market Size Estimation and Forecast by Vaccine Type, 2023-2033 (US$ Mn)
10.6 Market Size Estimation and Forecast by Vaccine Brand, 2023-2033 (US$ Mn)
10.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
10.8 Japan Meningococcal Vaccines Market Analysis
10.9 China Meningococcal Vaccines Market Analysis
10.10 India Meningococcal Vaccines Market Analysis
10.11 Australia Meningococcal Vaccines Market Analysis
10.12 South Korea Meningococcal Vaccines Market Analysis
10.13 Rest of Asia Pacific Meningococcal Vaccines Market Analysis

11 Latin America Meningococcal Vaccines Market Analysis
11.1 Key Findings
11.2 Latin America Meningococcal Vaccines Market Attractiveness Index
11.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
11.5 Market Size Estimation and Forecast by Vaccine Type, 2023-2033 (US$ Mn)
11.6 Market Size Estimation and Forecast by Vaccine Brand, 2023-2033 (US$ Mn)
11.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
11.8 Brazil Meningococcal Vaccines Market Analysis
11.9 Mexico Meningococcal Vaccines Market Analysis
11.10 Rest of Latin America Meningococcal Vaccines Market Analysis

12 MEA Meningococcal Vaccines Market Analysis
12.1 Key Findings
12.2 MEA Meningococcal Vaccines Market Attractiveness Index
12.3 Market Size by Country, 2023, 2028 & 2033 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
12.5 Market Size Estimation and Forecast by Vaccine Type, 2023-2033 (US$ Mn)
12.6 Market Size Estimation and Forecast by Vaccine Brand, 2023-2033 (US$ Mn)
12.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ Mn)
12.8 GCC Meningococcal Vaccines Market Analysis
12.9 South Africa Meningococcal Vaccines Market Analysis
12.10 Rest of MEA Meningococcal Vaccines Market Analysis

13 Company Profiles
13.1 Pipeline Analysis
13.2 Sanofi
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2015-2021
13.2.3.2 R&D Expenses, 2015-2021
13.2.3.3 Gross Profit, 2015-2021
13.2.3.4 Regional Market Share, 2021
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Merck & Co., Inc.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2015-2021
13.3.3.2 R&D Expenses, 2015-2021
13.3.3.3 Gross Profit, 2015-2021
13.3.3.4 Regional Market Share, 2021
13.3.4 Product Benchmarking
13.4 GSK plc
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2015-2021
13.4.3.2 R&D Expenses, 2015-2021
13.4.3.3 Gross Profit, 2015-2021
13.4.3.4 Regional Market Share, 2021
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Pfizer Inc.
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2015-2021
13.5.3.2 R&D Expenses, 2015-2021
13.5.3.3 Gross Profit, 2015-2021
13.5.3.4 Regional Market Share, 2021
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Serum Institute of India Pvt. Ltd.
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Product Benchmarking
13.7 Zhi Fei Biological
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Product Benchmarking
13.8 Incepta Pharmaceuticals Ltd.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.9 Walvax Biotechnology Co., Ltd.
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Product Benchmarking
13.10 BIO-MED
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Product Benchmarking

14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players

★調査レポート[世界の髄膜炎菌ワクチン市場2023年～2033年] (コード：VGA23FB017)販売に関する免責事項を必ずご確認ください。

★調査レポート[世界の髄膜炎菌ワクチン市場2023年～2033年]についてメールでお問い合わせ

MarketReport.jp

世界の髄膜炎菌ワクチン市場2023年～2033年

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料 総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp